Zymeworks will receive an $8 million milestone payment from Eli Lilly and Co. resulting from Lilly's investigational new drug application for an immuno-oncology bispecific antibody based on the Azymetric platform from Zymeworks as part of the companies' 2014 deal.
Lilly to pay $8M to Zymeworks for immuno-oncology drug milestone
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.